1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003; 42:1050–1065.
2. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13:745–753.
3. Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007; 13:3 Suppl. S1–S9.
4. Reinecke H, Matzkies F, Fobker M, Breithardt G, Schaefer RM. Diabetic nephropathy, percutaneous coronary interventions, and blockade of the renin-angiotensin system. Cardiology. 2005; 104:24–30.
5. Abe M, Morimoto T, Akao M, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014; 114:362–368.
6. Kim SM, Tripathy DR, Park SW, et al. Impact of chronic kidney disease on clinical outcomes in diabetic patients undergoing percutaneous coronary intervention in the era of newer-generation drug-eluting stents. Korean Circ J. 2017; 47:222–230.
7. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 2000; 102:2966–2972.
8. Peng JR, Chang CJ, Wang CL, Tung YC, Lee HF. Impact of chronic kidney disease on long-term outcome in coronary bypass candidates treated with percutaneous coronary intervention. Korean Circ J. 2017; 47:50–55.
9. Zhu ZB, Zhang RY, Zhang Q, et al. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT Study. Cardiology. 2009; 112:191–199.
10. Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014; 29:29–40.